Abstract
Abstract K-Ras inhibitor resistance in PDAC is associated with metabolic reprogramming towards a high OXPHOS state. Existing inhibitors of components of the electron transport chain have on-target toxicities that limit their use in the clinic, highlighting an opportunity to develop mechanistically orthogonal approaches. In this talk, I discuss our development of molecular glue degraders that target metabolic vulnerabilities in K-Ras inhibitor resistant PDAC. Citation Format: Fleur M. Ferguson. Overcoming the K-Ras inhibitor resistant cell state in PDAC with molecular glues [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr IA002.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
